124 related articles for article (PubMed ID: 34598061)
1. Mortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio.
Pinto-Paz ME; Cotrina-Concha JM; Benites-Zapata VA
Cancer Treat Res Commun; 2021; 29():100464. PubMed ID: 34598061
[TBL] [Abstract][Full Text] [Related]
2. Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study.
Wade RG; Robinson AV; Lo MCI; Keeble C; Marples M; Dewar DJ; Moncrieff MDS; Peach H
Ann Surg Oncol; 2018 Oct; 25(11):3341-3349. PubMed ID: 30066226
[TBL] [Abstract][Full Text] [Related]
3. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.
Huang K; Fan J; Misra S
J Surg Res; 2020 Jul; 251():329-339. PubMed ID: 32208196
[TBL] [Abstract][Full Text] [Related]
4. The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study.
Robinson AV; Keeble C; Lo MCI; Thornton O; Peach H; Moncrieff MDS; Dewar DJ; Wade RG
Cancer Immunol Immunother; 2020 Apr; 69(4):559-568. PubMed ID: 31974724
[TBL] [Abstract][Full Text] [Related]
5. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
6. Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
Lino-Silva LS; Salcedo-Hernández RA; García-Pérez L; Meneses-García A; Zepeda-Najar C
Melanoma Res; 2017 Apr; 27(2):140-144. PubMed ID: 28125448
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.
Garbe C; Orfanos CE
Pigment Cell Res; 1992; Suppl 2():285-94. PubMed ID: 1409431
[TBL] [Abstract][Full Text] [Related]
9. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
[TBL] [Abstract][Full Text] [Related]
10. Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study.
Utjés D; Lyth J; Lapins J; Eriksson H
Int J Cancer; 2017 Dec; 141(11):2243-2252. PubMed ID: 28799271
[TBL] [Abstract][Full Text] [Related]
11. Elevated neutrophil-lymphocyte ratio predicts mortality following elective endovascular aneurysm repair.
King AH; Schmaier AH; Harth KC; Kumins NH; Wong VL; Zidar DA; Kashyap VS; Cho JS
J Vasc Surg; 2020 Jul; 72(1):129-137. PubMed ID: 32037083
[TBL] [Abstract][Full Text] [Related]
12. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
[TBL] [Abstract][Full Text] [Related]
13. The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
Eriksson H; Lyth J; Andersson TM
Int J Cancer; 2016 Jun; 138(12):2829-36. PubMed ID: 26815934
[TBL] [Abstract][Full Text] [Related]
14. Baseline Serum neutrophil-to-lymphocyte ratio in acral melanoma compared with nonacral melanoma and its prognostic significance.
Choi ME; Jung JM; Kim DH; Won CH; Chang SE; Lee MW; Lee WJ
J Am Acad Dermatol; 2024 May; 90(5):977-985. PubMed ID: 38272394
[TBL] [Abstract][Full Text] [Related]
15. Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma.
Davis JL; Langan RC; Panageas KS; Zheng J; Postow MA; Brady MS; Ariyan C; Coit DG
Ann Surg Oncol; 2017 Jul; 24(7):1989-1996. PubMed ID: 28303429
[TBL] [Abstract][Full Text] [Related]
16. A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study.
Zaragoza J; Kervarrec T; Touzé A; Avenel-Audran M; Beneton N; Esteve E; Wierzbicka Hainaut E; Aubin F; Machet L; Samimi M
J Am Acad Dermatol; 2016 Oct; 75(4):712-721.e1. PubMed ID: 27544490
[TBL] [Abstract][Full Text] [Related]
17. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients.
Dimitriou N; Felekouras E; Karavokyros I; Alexandrou A; Pikoulis E; Griniatsos J
BMC Cancer; 2018 Dec; 18(1):1202. PubMed ID: 30509242
[TBL] [Abstract][Full Text] [Related]
18. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy.
Wagner NB; Luttermann F; Gassenmaier M; Forschner A; Leiter U; Garbe C; Eigentler TK
Australas J Dermatol; 2020 Aug; 61(3):e310-e318. PubMed ID: 32050042
[TBL] [Abstract][Full Text] [Related]
19. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Robinson A; Baetz T
Immunotherapy; 2020 Aug; 12(11):785-798. PubMed ID: 32657234
[No Abstract] [Full Text] [Related]
20. Early inflammatory biomarkers and melanoma survival.
Fortes C; Mastroeni S; Zappalà AR; Passarelli F; Ricci F; Abeni D; Michelozzi P
Int J Dermatol; 2023 Jun; 62(6):752-758. PubMed ID: 36872079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
